VYNT - Vyant Bio secures new U.S. patent for optical assay of human mixed cell population spheroids

The USPTO has issued Vyant Bio's ([[VYNT]] -0.4%) wholly-owned subsidiary, StemoniX, US Patent No. 11054408, titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids”. The patent covers a unique approach to applying human-induced Pluripotent Stem Cells (iPSCs) as a powerful tool to illuminate the biology of complex human cell types such as those of the central nervous system ((CNS)).The patent also covers the use of 3D co-cultures of cortical neurons and astrocytes displaying spontaneous, rhythmic, and highly-synchronized neural activity that can be visualized as calcium oscillations on standard, high-throughput fluorescent readers as a platform for CNS-based discovery efforts. The issuance of the 11054408 patent is the third patent granted to StemoniX: additional applications are currently pending worldwide.

For further details see:

Vyant Bio secures new U.S. patent for optical assay of human mixed cell population spheroids